莱卡内马布清晰度AD:早期阿尔茨海默病随机双盲第三期试验的生活质量结果
1Sharon Cohen, MD, FRCPC, Medical Director and Site Principal Investigator, 1 Valleybrook Drive, Suite 400, Toronto, Canada M3B 2S7, Tel: 416-386-9761; Fax: 416-386-0458, cohen@memorydisorders.ca.
The journal of prevention of Alzheimer's disease
|October 24, 2023
概括
在早期阿尔茨海默氏症中,莱卡内马布治疗显著改善了患者的健康相关生活质量 (HRQoL),并减少了护理人员的负担. 这些发现表明,对患者及其支持系统有重大益处.
科学领域:
- 神经科学是一个神经科学.
- 临床药理学 临床药理学
- 老年学是一门学科.
背景情况:
- 莱卡尼马布是一种单克隆抗体,向粉样β原纤维素.
- 第三阶段试验表明,lecanemab可降低粉样蛋白标记物,并减缓早期阿尔茨海默病的认知/功能衰退.
研究的目的:
- 评估来自Clarity AD第三期试验的与健康相关的生活质量 (HRQoL) 结果.
- 评估lecanemab对患者报告的生活质量和护理人员负担的影响.
主要方法:
- 克拉里蒂AD试验是一项为期18个月的多中心双盲研究.
- 患有早期阿尔茨海默氏症的参与者 (50-90岁) 接受了安慰剂或莱卡内马布 (10毫克/千克四次每两周一次).
- 使用EQ-5D-5L和QOL-AD测量HRQoL;用Zarit负担采访 (ZBI) 评估护理人员负担.
主要成果:
- 在18个月后,lecanemab治疗显示了患者报告的EQ-5D-5L和QOL-AD的统计学上显著改善,分别下降了49%和56%.
- 代理评级的QOL-AD也有所改善,下降幅度减少了23%.
- 用ZBI测量护理人员负担,与安慰剂相比,lecanemab组的护理人员负担下降了38%.
结论:
- 莱卡内马布治疗与早期阿尔茨海默病患者的健康相关生活质量保持有关.
- 该研究表明,护理人员负担显著减少.
- 这些患者报告的结果,以及认知和功能上的好处,表明lecanemab为患者,护理伙伴和社会提供了有意义的优势.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.8K
06:25Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
913
相关概念视频
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:30Dementia
120
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
120
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:20Antiepileptic Drugs: Potassium Channel Activators
192
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
192
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
131
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
131